Abstract:Damage to DNA is caused by ionizing radiation, genotoxic chemicals or collapsed replication forks. When DNA is damaged or cells fail to respond, a mutation that is associated with breast or ovarian cancer may occur. Mammalian cells control and stabilize the genome using a cell cycle checkpoint to prevent damage to DNA or to repair damaged DNA. Checkpoint kinase 2 (Chk2) is one of the important kinases, which strongly affects DNA-damage and plays an important role in the response to the breakage of DNA double-strands and related lesions. Therefore, this study concerns Chk2. Its purpose is to find potential inhibitors using the pharmacophore hypotheses (PhModels) and virtual screening techniques. PhModels can identify inhibitors with high biological activities and virtual screening techniques are used to screen the database of the National Cancer Institute (NCI) to retrieve compounds that exhibit all of the pharmacophoric features of potential inhibitors with high interaction energy. Ten PhModels were generated using the HypoGen best algorithm. The established PhModel, Hypo01, was evaluated by performing a cost function analysis of its correlation coefficient (r), root mean square deviation (RMSD), cost difference, and configuration cost, with the values 0.955, 1.28, 192.51, and 16.07, respectively. The result of Fischer’s cross-validation test for the Hypo01 model yielded a 95% confidence level, and the correlation coefficient of the testing set (rtest) had a best value of 0.81. The potential inhibitors were then chosen from the NCI database by Hypo01 model screening and molecular docking using the cdocker docking program. Finally, the selected compounds exhibited the identified pharmacophoric features and had a high interaction energy between the ligand and the receptor. Eighty-three potential inhibitors for Chk2 are retrieved for further study.

Progress in the Study of Cell Cycle Checkpoint Kinase 1 Inhibitors

Functions and Inhibitors of CHK1 in Cancer Therapy

Design, Synthesis and Biological Evaluation of Thienopyridinones As Chk1 Inhibitors

Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.

Cyclin Dependent Kinase 1 Inhibitors: a Review of Recent Progress.

Discovery of pyrido[3,2- d ]pyrimidin-6(5 H )-one derivatives as checkpoint kinase 1 (CHK1) inhibitors with potent antitumor efficacy

Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors

The Research Progress of the Mechanism of CHK2 in Tumor

Implications for Chk1 Regulation: the 1.7 Å Crystal Structure of Human Cell Cycle Checkpoint Kinase Chk1

Design checkpoint kinase 2 inhibitors by pharmacophore modeling and virtual screening techniques.

Discovery and Development of a Potent, Selective, and Orally Bioavailable CHK1 Inhibitor Candidate: 5-((4-((3-Amino-3-methylbutyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)picolinonitrile

Targeting the checkpoint kinases: chemosensitization versus chemoprotection

Progress in Clinical Trails of Cyclin Dependent Kinase Inhibitors

3D-QSAR Study of Chk1 Kinase Inhibitors Based on Docking

Characterization of the CHK1 allosteric inhibitor binding site.

Progress and Development in Research of Mitotic Kinases Inhibitors

Research Advances in Anticancer Cyclin-dependent-kinase Inhibitors

Synthesis and Biological Evaluation of 2,6-Disubstituted-9h-purine, 2,4-Disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine Analogues As Novel CHK1 Inhibitors.

Advances on the Study of PLK1 Inhibitors As Antitumor Agents

Inhibitors of cell cycle checkpoint target Wee1 kinase – a patent review (2003–2022)

Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale